IMTX
Immatics NVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.28B
P/E Ratio
—
EPS
$-1.97
Beta
1.30
52W High
$12.41
52W Low
$5.05
50-Day MA
$10.78
200-Day MA
$9.72
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immatics NV
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany.
Fundamentals
| Revenue (TTM) | $37.30M |
| Gross Profit (TTM) | $-163.81M |
| EBITDA | $-203.93M |
| Operating Margin | -868.00% |
| Return on Equity | -43.20% |
| Return on Assets | -22.40% |
| Revenue/Share (TTM) | $0.30 |
| Book Value | $4.21 |
| Price-to-Book | 2.44 |
| Price-to-Sales (TTM) | 34.37 |
| EV/Revenue | 18.03 |
| EV/EBITDA | 7.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -59.00% |
| Shares Outstanding | $136.67M |
| Float | $69.59M |
| % Insiders | 17.58% |
| % Institutions | 79.85% |
Historical Volatility
HV 10-Day
66.55%
HV 20-Day
59.29%
HV 30-Day
56.96%
HV 60-Day
49.10%
HV Rank
41.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($18.77 target)
10
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026